November 22, 2024
The Globe and Mail | Rare milestone for Canadian biotech as Zymeworks-developed drug gets FDA approval
David Martin, Head of Bloom Burton Equity Research comments in the Globe and Mail on the milestone achievement for Zymeworks (NASDAQ: ZYME).
On November 21, 2024, the U.S. Food and Drug Administration approved the use of the company’s lead cancer drug zanidatamab, a tumour-fighting antibody to treat adults with a form of biliary-tract cancer for the U.S. market.
